National Breast and Cervical
Cancer Early Detection Program (NBCCEDP) Monitoring Activities
Revision of a currently approved collection
No
Regular
11/18/2021
Requested
Previously Approved
36 Months From Approved
11/30/2021
1,400
910
1,228
764
38,976
38,976
CDC is required to monitor and
evaluate processes and outcomes for the NBCCEDP. Recipients are
required to report information to CDC to support these efforts.
Based on the redesigned NBCCEDP under DP22-2202, CDC developed a
logic model to illustrate the strategies and expected outcomes
associated with the NBCCEDP over time (Attachment 3 – DP22-2202
NBCCEDP Logic Model). In contrast to DP17-1701, DP22-2202 has a
stronger focus on selecting and engaging partners to support
NBCCEDP implementation, including serving populations
disproportionately burdened by breast and/or cervical cancer and
tracking them through screening completion. As illustrated in the
logic model, CDC anticipates that recipients’ implementation of the
five strategies and activities described will result in several
desired short-, intermediate-, and long-term outcomes, including
increased breast and cervical screening rates. The logic model
guided development of CDC’s NBCCEDP monitoring and evaluation plan,
which includes evaluation questions and sub-questions that map to
the proposed information collections (Attachment 4 – NBCCEDP
Evaluation Question Matrix) to be addressed through systematic
monitoring and evaluation of these key strategies and the primary
outcome of screening rate changes over time. In 2022, CDC will
issue a new Notice of Funding Opportunity (DP22-2202) to continue
this mission with a stronger focus on collaborating with other
public health programs and community-based organizations to serve
populations disproportionately burdened by breast and/or cervical
cancer. Based on data collection conducted throughout DP17-1701 and
consistent with programmatic changes, the information collection
plan has also been revised to update existing and add new data
collection instruments and integrate the previously approved MDEs
into this single approval package to increase efficiency. DP22-2202
is expected to fund the same number of recipients (N=70).
US Code:
42
USC 300k Name of Law: Breast and Cervical Cancer Mortality
Prevention Act of 1990
PL:
Pub.L. 101 - 354 2 Name of Law: Breast and Cervical Cancer
Prevention and Treatment Act of 2000
These revisions were made to
improve data quality. Because revisions increased the number of
questions in the annual survey, burden hours increased from 56 to
65 burden hours. Revisions to the clinic-level data collection did
not result in increased burden; therefore, the estimated burden
remains the same. The QPU is new and involves four annual
submissions for all 70 recipients for a net increase of 104
estimated burden hours. The service delivery projection worksheet
is also new and involves an annual submission for all 70 recipients
for a net increase of 34 estimated burden hours. There were no
changes to the MDEs; therefore, the estimated burden remains the
same.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.